1-7 of 7
Andrew E. Aplin
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Packing a Punch against PD-L1

Claudia Capparelli, Andrew E. Aplin
Journal: Cancer Discovery
Cancer Discov (2022) 12 (6): 1413–1415.
https://doi.org/10.1158/2159-8290.CD-22-0301
Published: 02 June 2022
View article titled, Packing a Punch against PD-L1
Open the PDF for Packing a Punch against PD-L1 in another window
Journal Articles

From the Community to the Bench and Back Again: The Value of Patient and Community Engagement in Cancer Research

Amy E. Leader, Andrew E. Aplin
Journal: Cancer Discovery
Cancer Discov (2021) 11 (9): 2135–2138.
https://doi.org/10.1158/2159-8290.CD-21-0693
Published: 01 September 2021
View article titled, From the Community to the Bench and Back Again: The Value of Patient and Community Engagement in Cancer Research
Open the PDF for From the Community to the Bench and Back Again: The Value of Patient and Community Engagement in Cancer Research in another window
Journal Articles

Fueling the Fire: Inflammatory Forms of Cell Death and Implications for Cancer Immunotherapy

Sheera R. Rosenbaum, Nicole A. Wilski, Andrew E. Aplin
Journal: Cancer Discovery
Cancer Discov (2021) 11 (2): 266–281.
https://doi.org/10.1158/2159-8290.CD-20-0805
Published: 02 February 2021
View article titled, Fueling the Fire: Inflammatory Forms of Cell Death and Implications for Cancer Immunotherapy
Open the PDF for Fueling the Fire: Inflammatory Forms of Cell Death and Implications for Cancer Immunotherapy in another window
Journal Articles

Mutant BRAF and MEK Inhibitors Regulate the Tumor Immune Microenvironment via Pyroptosis

Dan A. Erkes, Weijia Cai, Ileine M. Sanchez, Timothy J. Purwin, Corey Rogers, Conroy O. Field, Adam C. Berger, Edward J. Hartsough, Ulrich Rodeck, Emad S. Alnemri, Andrew E. Aplin
Journal: Cancer Discovery
Cancer Discov (2020) 10 (2): 254–269.
https://doi.org/10.1158/2159-8290.CD-19-0672
Published: 05 February 2020
View article titled, Mutant BRAF and MEK Inhibitors Regulate the Tumor Immune Microenvironment via Pyroptosis
Open the PDF for Mutant BRAF and MEK Inhibitors Regulate the Tumor Immune Microenvironment via Pyroptosis in another window
Includes: Supplementary data
Journal Articles

Correction: In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2–CDK4/6 Targeting and mTOR–S6 Resistance Mechanisms

Jessica L.F. Teh, Phil F. Cheng, Timothy J. Purwin, Neda Nikbakht, Prem Patel, Inna Chervoneva, Adam Ertel, Paolo M. Fortina, Ines Kleiber, Kim HooKim, Michael A. Davies, Lawrence N. Kwong, Mitch P. Levesque, Reinhard Dummer, Andrew E. Aplin
Journal: Cancer Discovery
Cancer Discov (2018) 8 (12): 1654.
https://doi.org/10.1158/2159-8290.CD-18-1291
Published: 03 December 2018
View article titled, Correction: <em>In Vivo</em> E2F Reporting Reveals Efficacious Schedules of MEK1/2–CDK4/6 Targeting and mTOR–S6 Resistance Mechanisms
Open the PDF for Correction: <em>In Vivo</em> E2F Reporting Reveals Efficacious Schedules of MEK1/2–CDK4/6 Targeting and mTOR–S6 Resistance Mechanisms in another window
Journal Articles

In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2–CDK4/6 Targeting and mTOR–S6 Resistance Mechanisms

Jessica L.F. Teh, Phil F. Cheng, Timothy J. Purwin, Neda Nikbakht, Prem Patel, Inna Chervoneva, Adam Ertel, Paolo M. Fortina, Ines Kleiber, Kim HooKim, Michael A. Davies, Lawrence N. Kwong, Mitch P. Levesque, Reinhard Dummer, Andrew E. Aplin
Journal: Cancer Discovery
Cancer Discov (2018) 8 (5): 568–581.
https://doi.org/10.1158/2159-8290.CD-17-0699
Published: 30 April 2018
View article titled, <em>In Vivo</em> E2F Reporting Reveals Efficacious Schedules of MEK1/2–CDK4/6 Targeting and mTOR–S6 Resistance Mechanisms
Open the PDF for <em>In Vivo</em> E2F Reporting Reveals Efficacious Schedules of MEK1/2–CDK4/6 Targeting and mTOR–S6 Resistance Mechanisms in another window
Includes: Supplementary data
Journal Articles

A Preexisting Rare PIK3CAE545K Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in NRAS Melanoma and Is Dependent on S6K1 Signaling

Gabriele Romano, Pei-Ling Chen, Ping Song, Jennifer L. McQuade, Roger J. Liang, Mingguang Liu, Whijae Roh, Dzifa Y. Duose, Fernando C.L. Carapeto, Jun Li, Jessica L.F. Teh, Andrew E. Aplin, Merry Chen, Jianhua Zhang, Alexander J. Lazar, Michael A. Davies, P. Andrew Futreal, Rodabe N. Amaria, David Y. Zhang, Jennifer A. Wargo, Lawrence N. Kwong
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2018) 8 (5): 556–567.
https://doi.org/10.1158/2159-8290.CD-17-0745
Published: 30 April 2018
View article titled, A Preexisting Rare <em>PIK3CA</em><sup>E545K</sup> Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in <em>NRAS</em> Melanoma and Is Dependent on S6K1 Signaling
Open the PDF for A Preexisting Rare <em>PIK3CA</em><sup>E545K</sup> Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in <em>NRAS</em> Melanoma and Is Dependent on S6K1 Signaling in another window
Includes: Supplementary data